NCT05452525

Pharmacokinetics and Safety/Tolerability Profile of CKD-379

A Randomized, Open-label, Single Dose, 3-period, 6-treatment, Crossover Study to Compare the Pharmacokinetics and Safety/Tolerability of CKD-379 and Coadministration of D759, D745 and D150 in Healthy Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 24 (actual)
• Sponsor: Chong Kun Dang Pharmaceutical · Industry
• Sex: All
• Age: 19 Years – 50 Years
• Healthy volunteers: Accepted

Summary

A study to compare the pharmacokinetics and safety/tolerability between CKD-379 tablet and D759, D745, D150 combination

Detailed description

A randomized, open-label, single dose, 3-period, 6-treatment, crossover study to compare the pharmacokinetics and safety/tolerability of CKD-379 in healthy subjects under fed conditions

Conditions

• Type II Diabetes Mellitus

Interventions

Type	Name	Description
DRUG	CKD-379 I	1 tablet administration under fed condition
DRUG	CKD-379 II	1 tablet administration under fed condition
DRUG	D759+D745+D150	3 tablet coadministration under fed condition

Timeline

• Start date: 2022-07-26
• Primary completion: 2022-08-27
• Completion: 2022-09-21
• First posted: 2022-07-11
• Last updated: 2022-10-18

Locations

1 site across 1 country: South Korea